Johnson & Johnson $JNJ Stake Raised by Blue Rock Wealth Management LLC

Key Points

• Blue Rock Wealth Management LLC increased its stake in Johnson & Johnson by 324.5%, owning a total of 6,486 shares valued at $1,076,000.
• Institutional ownership of Johnson & Johnson stands at 69.55%, as major investors like Nuveen LLC and GAMMA Investing LLC have significantly increased their stakes in the company.
• Analyst ratings are generally positive, with Johnson & Johnson receiving a Moderate Buy consensus and a target price increase from UBS Group, raising it to $190.00.

Blue Rock Wealth Management LLC boosted its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 324.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,486 shares of the company's stock after purchasing an additional 4,958 shares during the period. Johnson & Johnson makes up about 0.9% of Blue Rock Wealth Management LLC's portfolio, making the stock its 24th largest holding. Blue Rock Wealth Management LLC's holdings in Johnson & Johnson were worth $1,076,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Nuveen LLC acquired a new position in shares of Johnson & Johnson in the first quarter worth $1,369,188,000. GAMMA Investing LLC lifted its stake in shares of Johnson & Johnson by 24,450.4% in the first quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company's stock valued at $1,196,596,000 after buying an additional 7,185,977 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Johnson & Johnson by 26.4% in the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock valued at $3,844,580,000 after buying an additional 4,842,582 shares during the period. Pacer Advisors Inc. lifted its stake in shares of Johnson & Johnson by 1,382.0% in the first quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company's stock valued at $502,509,000 after buying an additional 2,825,626 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $349,206,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. UBS Group increased their target price on shares of Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research note on Thursday, July 17th. Bank of America increased their price target on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research report on Thursday, July 17th. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their price target for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Finally, Wall Street Zen lowered shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a report on Friday, September 5th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, Johnson & Johnson has a consensus rating of "Moderate Buy" and a consensus target price of $176.29.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business's stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company's stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Trading Down 0.6%

JNJ opened at $177.12 on Wednesday. The stock has a market capitalization of $426.57 billion, a P/E ratio of 18.94, a P/E/G ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $181.16. The firm's fifty day simple moving average is $169.51 and its 200 day simple moving average is $161.02. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm's revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.9%. Johnson & Johnson's payout ratio is 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.